To investigate whether blocking BRAFi-induced autophagy–lysosomal activation alters melanoma response to BRAF-targeted therapy, we used TFEBKD A375 cells reconstituted with WT or mutant TFEB (Fig. 8a). Here, TFEB is linked to melanoma.